secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001104659-24-034204
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering doses first patient in Phase 2a of IMM-1-104; Phase 1 data shows safety and biomarker activity
--------------------------------------------------------------------------------

- First patient dosed in Phase 2a of IMM-1-104; ~150 patients planned across 5 arms (monotherapy and combination).
- Phase 1 (N=41): no grade 4 TRAEs; only one grade 3 (reversible rash); most common grade 1/2: diarrhea 19.5%, nausea 19.5%.
- At 320mg, pERK inhibition ≥90% for 2.7h; 100% of evaluable patients (N=22) showed no new RAS or MAPK pathway mutations by ctDNA.
- 53% of patients had ≥1 target lesion regression at 240/320mg; best individual regression -35.7% at 320mg in second-line.
- Thomas J. Schall, Ph.D. appointed to Board of Directors as Class I Director effective March 11, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000110465924034204/0001104659-24-034204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000110465924034204/tm248799d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-034204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer